These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24894944)

  • 1. EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
    Poonia S; Berge EM; Aisner DL; Damek D; Doebele RC
    Clin Lung Cancer; 2014 Sep; 15(5):387-9. PubMed ID: 24894944
    [No Abstract]   [Full Text] [Related]  

  • 2. Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better.
    Cessot A; Blanchet B; Goldwasser F
    Ann Oncol; 2014 Oct; 25(10):2093-2094. PubMed ID: 25057169
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
    Kuiper JL; Smit EF
    Lung Cancer; 2013 Apr; 80(1):102-5. PubMed ID: 23375403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
    Baty F; Rothschild S; Früh M; Betticher D; Dröge C; Cathomas R; Rauch D; Gautschi O; Bubendorf L; Crowe S; Zappa F; Pless M; Brutsche M;
    PLoS One; 2013; 8(9):e72966. PubMed ID: 24039832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
    Berge EM; Aisner DL; Doebele RC
    J Thorac Oncol; 2013 Sep; 8(9):e83-4. PubMed ID: 23945392
    [No Abstract]   [Full Text] [Related]  

  • 6. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
    Locatelli-Sanchez M; Couraud S; Arpin D; Riou R; Bringuier PP; Souquet PJ
    Lung; 2013 Oct; 191(5):491-9. PubMed ID: 23749122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.
    Chiba S; Akiyama M; Yakuwa K; Sato H; Hirano K; Utsumi Y; Nagashima H; Sugai T; Maemondo M
    Ann Palliat Med; 2022 Aug; 11(8):2745-2750. PubMed ID: 34806395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
    Sun JM; Won YW; Kim ST; Kim JH; Choi YL; Lee J; Park YH; Ahn JS; Park K; Ahn MJ
    J Cancer Res Clin Oncol; 2011 Apr; 137(4):687-94. PubMed ID: 20552223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
    Ackerman A; Goldstein MA; Kobayashi S; Costa DB
    J Thorac Oncol; 2012 Oct; 7(10):e19-20. PubMed ID: 22982663
    [No Abstract]   [Full Text] [Related]  

  • 10. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
    Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
    Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
    Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
    Katono K; Kasajima M; Ishihara M; Hayashi N; Nagashima Y; Igawa S; Masuda N
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):375-7. PubMed ID: 23507602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
    Tamiya A; Tamiya M; Nishihara T; Shiroyama T; Nakao K; Tsuji T; Takeuchi N; Isa SI; Omachi N; Okamoto N; Suzuki H; Okishio K; Iwazaki A; Imai K; Hirashima T; Atagi S
    Anticancer Res; 2017 Aug; 37(8):4177-4182. PubMed ID: 28739703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
    Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
    Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib.
    Yang J; Yang J; Ban S; Li X; Chen X; Yang J; Qian J
    J Thorac Oncol; 2019 Sep; 14(9):e198-e200. PubMed ID: 31445735
    [No Abstract]   [Full Text] [Related]  

  • 16. Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib.
    Smith JT; Puri S; Akerley W
    Clin Lung Cancer; 2023 Jun; 24(4):360-361. PubMed ID: 36935243
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature.
    How J; Mann J; Laczniak AN; Baggstrom MQ
    Clin Lung Cancer; 2017 Jul; 18(4):354-363. PubMed ID: 28245967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
    Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
    Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.